Halozyme Announces Roche Receives FDA Approval For Phesgo(TM) (F
HALO: Halozyme Therapeutics, Inc.
2020-06-29 12:54:00
Halozyme Announces Roche Receives FDA Approval For Phesgo(TM) (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer
2020-06-29 12:54:00
Halozyme Announces Roche Receives FDA Approval For Phesgo(TM) (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer